July 23, 2018 09:30 AM EDT
R&D
Pharma

Lil­ly inks R&D deal with An­i­ma, pay­ing $44M in re­search fund­ing and up­front pay­ments

Brittany Meiling

Eli Lil­ly $LLY is com­mis­sion­ing a small team in New Jer­sey to im­ple­ment its un­usu­al ap­proach to drug dis­cov­ery on a few of Lil­ly’s tar­gets …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times